In conclusion, clear PK and TE results in pre-clinical animal models, in conjunction with rat toxicology data showing adverse safety findings of human WT BMP9 and the lack of efficacy in the standard MCT rat model, a therapeutic window for treatment of PAH could not be identified. This evidence concerns the gene GDF2 and pulmonary arterial hypertension.